Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines

Genes Chromosomes and Cancer

Volumn 37, Issue 2, 2003, Pages 121-131

  Tillinghast, Guy W ^a   Partee, Jason ^a   Albert, Paul ^a   Kelley, Jenny M ^a   Burtow, Kenneth H ^a   Kelly, Kathleen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; PROTEIN P300;

ALLELE; ARTICLE; CANCER CELL; ENZYME ACTIVITY; GENE DOSAGE; GENE LOCUS; GENE LOSS; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; GENETIC STABILITY; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY LOSS; HUMAN; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE;

CHROMOSOME ABERRATIONS; CREB-BINDING PROTEIN; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, NEOPLASM; GENETIC MARKERS; HL-60 CELLS; HT29 CELLS; HUMANS; K562 CELLS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; NUCLEAR PROTEINS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0038747041     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10195     Document Type: Article

References (31)

1. Arany Z, Sellers WR, Livingston DM, Eckner R. 1994. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 77:799-800.
2. Avantaggiati ML, Carbone M, Graessmann A, Nakatani Y, Howard B. Levine AS. 1996. The SV40 large T antigen and adenovirus E la oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J 15:2236-2248.
3. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175-1184.
4. Bannister AJ, Kouzarides T. 1996. The CBP co-acdvator is a histone acetyltransferase. Nature 384:641-643.
5. Carney R, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD. 1985. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913-2923.
6. Chakravarti D, Ogryzko V, Kao HY, Nash A, Chen H, Nakatani Y, Evans RM. 1999. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96:393-403.
7. Chan HM, La Thangue NB. 2001. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114:2363-2373.
8. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM. 1994. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor, Genes Dev 8:869-884.
9. Fleiss JL. 1981. Statistical Methods for Rates and Proportions. New York: Wiley-Liss.
10. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin S-F, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JDA, Ponder BAJ, Kouzarides T, Caldas C. 2000. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24:300-303.
11. Giles RH, Peters DJ, Breuning MH. 1998. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178-183.
12. Giordano A, Avantaggiati ML. 1999. p300 and CBP: partners for life and death. J Cell Physiol 181:218-230.
13. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. 2000. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60:4894-4906.
14. Goodman RH, Smolik S. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-1577.
15. Gu W, Roeder RG. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
16. Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY, Nakatani Y, Kedes L. 1999. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96:405-413.
17. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S-C, Heyman RA, Rose DW, Glass CK, Rosenfeld MG. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414.
18. Kung AL, Rebel VI, Bronson RT, Ch'ng L-K, Sieff CA, Livingston DM, Yao T-P. 2000. Gene dosage-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14:272-277.
19. Lida A, Kurose K, Isobe R, Akiyama F, Sakamoto G, Yoshimoto M, Kasumi F, Nakamura Y, Emi M. 1998. Mapping of a new target region of allelic loss to a 2-Cm interval at 22q13.1 in primary breast cancer. Genes Chromosomes Cancer 21:108-112.
20. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. 1997. Binding and modulation of p53 by p300/CBP coactivators, Nature 387:823-827.
21. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong J-M, Iwama T, Miyaki M. 1996. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12:1565-1569.
22. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Kohn KW. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Research 57:4285-4300.
23. Ogoryzko VV, Schiltz RL, Russanova V, Howard B, Nakatani Y. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959.
24. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, Breuning MH. 1995. Rubinstein-Taybi syndrome caused by murations in the transcriptional co-activator CBP. Nature 376:348-351.
25. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA Jr. Carney D, Minna JD, Mulshine JL. 1996. NCI-Navy medical oncology branch cell line data base. Cell Biochem Suppl 34:32-91.
26. Ponting CP, Blake DJ, Daview KE, Kendrick-Jones J, Winder SJ. 1996. AA and TAZ: new putative zinc fingers in dystrophin and other proteins. Trends Biochem Sci 21:11-13.
27. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, lyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. 2000. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235.
28. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Meyers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Borstein D, Brown PQ, Weinstein JN. 2000. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244.
29. Schule R, Evans RM. 1991. Cross-coupling of signal transduction pathways: zinc finger meets leucine zipper. Trends Genet 7:377-381.
30. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. 1996. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324.
31. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361-372.